AP3619A - Smac mimetic - Google Patents

Smac mimetic

Info

Publication number
AP3619A
AP3619A AP2012006066A AP2012006066A AP3619A AP 3619 A AP3619 A AP 3619A AP 2012006066 A AP2012006066 A AP 2012006066A AP 2012006066 A AP2012006066 A AP 2012006066A AP 3619 A AP3619 A AP 3619A
Authority
AP
ARIPO
Prior art keywords
smac mimetic
smac
mimetic
Prior art date
Application number
AP2012006066A
Other languages
English (en)
Other versions
AP2012006066A0 (en
Inventor
Stephen M Condon
Yijun Deng
Matthew G Laporte
Susan R Rippin
Original Assignee
Tetralogic Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43411387&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP3619(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tetralogic Pharm Corp filed Critical Tetralogic Pharm Corp
Publication of AP2012006066A0 publication Critical patent/AP2012006066A0/xx
Application granted granted Critical
Publication of AP3619A publication Critical patent/AP3619A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/46—Amines, e.g. putrescine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AP2012006066A 2009-07-02 2010-06-25 Smac mimetic AP3619A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22266809P 2009-07-02 2009-07-02
US12/819,221 US8283372B2 (en) 2009-07-02 2010-06-20 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
PCT/US2010/039976 WO2011002684A1 (fr) 2009-07-02 2010-06-25 Mimétique de smac

Publications (2)

Publication Number Publication Date
AP2012006066A0 AP2012006066A0 (en) 2012-02-29
AP3619A true AP3619A (en) 2016-02-29

Family

ID=43411387

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2012006066A AP3619A (en) 2009-07-02 2010-06-25 Smac mimetic

Country Status (27)

Country Link
US (10) US8283372B2 (fr)
EP (1) EP2448923B8 (fr)
JP (1) JP5674780B2 (fr)
KR (1) KR101755218B1 (fr)
CN (1) CN102471275B (fr)
AP (1) AP3619A (fr)
AR (1) AR077629A1 (fr)
AU (1) AU2010266525C1 (fr)
BR (1) BRPI1013958B1 (fr)
CA (1) CA2766162C (fr)
CL (1) CL2011003333A1 (fr)
CO (1) CO6480975A2 (fr)
DK (1) DK2448923T3 (fr)
EA (1) EA022061B1 (fr)
EC (1) ECSP11011557A (fr)
ES (1) ES2565337T3 (fr)
HK (2) HK1169410A1 (fr)
HU (1) HUE026982T2 (fr)
IL (1) IL217237A (fr)
MX (1) MX2011013819A (fr)
MY (1) MY153116A (fr)
NZ (1) NZ597051A (fr)
PE (1) PE20131173A1 (fr)
SG (1) SG177404A1 (fr)
TW (1) TWI485148B (fr)
WO (1) WO2011002684A1 (fr)
ZA (1) ZA201109342B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006020060A2 (fr) 2004-07-15 2006-02-23 Tetralogic Pharmaceuticals Corporation Composes de liaison aux proteines iap
AU2006216450C1 (en) 2005-02-25 2013-01-10 Medivir Ab Dimeric IAP inhibitors
US20100317593A1 (en) * 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
CA2767064C (fr) 2009-07-02 2017-11-07 Sanofi Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
UY33236A (es) * 2010-02-25 2011-09-30 Novartis Ag Inhibidores dimericos de las iap
UY33794A (es) 2010-12-13 2012-07-31 Novartis Ag Inhibidores diméricos de las iap
AU2012315986A1 (en) * 2011-09-30 2014-04-17 Srinivas Chunduru Smac mimetic (birinapant) for use in the treatment of proliferative diseases (cancer)
US20130196927A1 (en) * 2012-01-27 2013-08-01 Christopher BENETATOS Smac Mimetic Therapy
JP2015524441A (ja) * 2012-08-01 2015-08-24 テトラロジック ファーマシューティカルズ コーポレーション 併用療法
KR20200108903A (ko) 2013-06-25 2020-09-21 더 월터 앤드 엘리자 홀 인스티튜트 오브 메디컬 리서치 세포내 감염의 치료 방법
WO2015017520A1 (fr) * 2013-07-30 2015-02-05 Tetralogic Pharmaceuticals Corp. Procédé de traitement
WO2016079527A1 (fr) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Polythérapie
WO2016097773A1 (fr) 2014-12-19 2016-06-23 Children's Cancer Institute Antagonistes des iap thérapeutiques pour traiter des troubles prolifératifs
CN108883187A (zh) * 2016-02-24 2018-11-23 东安大略儿童医院研究所 用于癌症治疗的smc联合疗法
CN109071508B (zh) * 2016-04-27 2021-09-03 南京明德新药研发股份有限公司 作为新型二价iap拮抗剂的苯并咪唑联吲哚化合物
WO2019080928A1 (fr) * 2017-10-27 2019-05-02 南京明德新药研发股份有限公司 Forme cristalline d'un antagoniste d'iap et procédé de préparation correspondant
US11590197B2 (en) 2017-11-01 2023-02-28 The Regents Of The University Of California Agents targeting inhibitor of apoptosis proteins
US10944377B2 (en) * 2017-12-31 2021-03-09 Skyworks Solutions, Inc. Broadband power splitter
CN111655713B (zh) * 2018-02-09 2023-06-27 广东东阳光药业有限公司 Iap抑制剂及其在药物中的应用
CN112533898A (zh) 2018-07-31 2021-03-19 日商泛美克斯股份有限公司 杂环化合物
US10870663B2 (en) 2018-11-30 2020-12-22 Glaxosmithkline Intellectual Property Development Limited Compounds useful in HIV therapy
JPWO2021020585A1 (fr) 2019-07-31 2021-02-04
CN112521372B (zh) * 2019-09-18 2022-07-08 南京华威医药科技集团有限公司 一种细胞凋亡蛋白抑制剂及其制备方法和用途
CN112778398A (zh) * 2019-11-07 2021-05-11 杜心赟 肝靶向药、其药物组合物及其用途
EP4093394A1 (fr) 2020-01-20 2022-11-30 Astrazeneca AB Inhibiteurs de tyrosine kinase du récepteur du facteur de croissance épidermique pour le traitement du cancer
US20240083846A1 (en) * 2020-12-17 2024-03-14 Council Of Scientific & Industrial Research Smac mimetics for treatment of cancer, process for preparation and pharmaceutical composition thereof
WO2023194547A1 (fr) 2022-04-08 2023-10-12 Medivir Ab Polymorphe h de birinapant
WO2023230432A1 (fr) 2022-05-23 2023-11-30 Inhibrx, Inc. Polythérapie à base d'agoniste de dr5 et d'antagoniste d'iap
WO2024133721A1 (fr) 2022-12-21 2024-06-27 Step Pharma S.A.S. Combinaisons d'un inhibiteur de ctps1 et d'un inhibiteur d'iap pour une utilisation dans le traitement du cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060194741A1 (en) * 2005-02-25 2006-08-31 Condon Stephen M Dimeric IAP inhibitors
US20080119532A1 (en) * 2004-03-01 2008-05-22 Board Of Regents, The University Of Texas System Dimeric Small Molecule Potentiators of Apoptosis

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3832253A (en) 1973-03-21 1974-08-27 Baxter Laboratories Inc Method of making an inflatable balloon catheter
DE2714880A1 (de) 1977-04-02 1978-10-26 Hoechst Ag Cephemderivate und verfahren zu ihrer herstellung
EP0049898B2 (fr) 1980-10-15 1991-08-14 Takeda Chemical Industries, Ltd. Procédé d'essai immunochimique et trousse de réactifs
US4667014A (en) 1983-03-07 1987-05-19 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US4525300A (en) 1983-01-07 1985-06-25 Japanese Foundation For Cancer Research Human leukemia virus-related peptides, antibodies of the peptides and a process for production of the antibodies
CA1200416A (fr) 1983-05-13 1986-02-11 Societe Des Produits Nestle S.A. Procede de production de produit alimentaire
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4935493A (en) 1987-10-06 1990-06-19 E. I. Du Pont De Nemours And Company Protease inhibitors
US5208007A (en) 1988-11-22 1993-05-04 Board Of Regents Of The University Of Oklahoma Isotopic tracer composition and method for making and using same
US5023077A (en) 1989-01-24 1991-06-11 Aphton Corporation Immunogenic compositions and methods for the treatment and prevention of gastric and duodenal ulcer disease
US5545719A (en) 1990-05-01 1996-08-13 Neuromedica, Inc. Nerve growth peptides
JPH04167172A (ja) 1990-10-31 1992-06-15 Nec Corp ベクトルプロセッサ
DE4105480A1 (de) 1991-02-21 1992-08-27 Boehringer Mannheim Gmbh Verbesserte aktivierung von rekombinanten proteinen
US5831002A (en) 1992-05-20 1998-11-03 Basf Aktiengesellschaft Antitumor peptides
EP0656368B2 (fr) 1992-08-05 2003-06-04 Meito Sangyo Kabushiki Kaisha Composite de petit diametre constitue de carboxypolysaccharide hydrosoluble et d'oxyde de fer magnetique
DE69230043T2 (de) 1992-12-11 2000-01-27 University Of Florida, Gainesville Materialien und methoden zur schädlingsbekämpfung
US5468494A (en) 1993-11-12 1995-11-21 Aphton Corp. Immunogenic compositions against human gastrin 17
US5688506A (en) 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
US5527775A (en) 1994-10-13 1996-06-18 Enzon, Inc. Reduction of mammalian neoplasms with phospholipase A2 activating substances
US6187557B1 (en) 1995-08-08 2001-02-13 Tularik Inc. c-IAP1 and c-IAP2: inhibitors of apoptosis
US5786173A (en) 1996-03-19 1998-07-28 Idun Pharmaceuticals, Inc. MCH4 and MCH5, apoptotic protease, nucleic acids encoding and methods of use
US6133437A (en) 1997-02-13 2000-10-17 Apoptogen, Inc. Modulation of IAPs for the treatment of proliferative diseases
US5961955A (en) 1997-06-03 1999-10-05 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope
US5977311A (en) 1997-09-23 1999-11-02 Curagen Corporation 53BP2 complexes
US6110691A (en) 2000-01-06 2000-08-29 Board Of Regents, The University Of Texas System Activators of caspases
US6608026B1 (en) 2000-08-23 2003-08-19 Board Of Regents, The University Of Texas System Apoptotic compounds
AU2001286730A1 (en) 2000-08-24 2002-03-04 Thomas Jefferson University An iap binding peptide or polypeptide and methods of using the same
US6992063B2 (en) 2000-09-29 2006-01-31 The Trustees Of Princeton University Compositions and method for regulating apoptosis
WO2002026775A2 (fr) 2000-09-29 2002-04-04 Trustees Of Princeton University Compositions et methodes de regulation de l'apoptose
WO2002030959A2 (fr) 2000-10-13 2002-04-18 Abbott Laboratories Peptides derives de smac (diablo) et procedes d'utilisation de ceux-ci
US20020160975A1 (en) 2001-02-08 2002-10-31 Thomas Jefferson University Conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO for mediating apoptosis
MXPA03010762A (es) 2001-05-31 2005-03-07 Univ Princeton Peptidos enlazantes de iap y ensayos para identificar los compuestos que enlazan el iap.
EP1420786A2 (fr) 2001-08-23 2004-05-26 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Procedes d'inhibition de la formation de canaux vasculaires et procedes d'inhibition de la proliferation
US6911426B2 (en) 2001-11-21 2005-06-28 The Burnham Institute Methods and compositions for derepression of IAP-inhibited caspase
US20060258581A1 (en) 2001-11-21 2006-11-16 Reed John C Methods and composition for derepressions of IAP-inhibited caspase
US20060128632A1 (en) 2002-07-02 2006-06-15 Sharma Sushil K Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
DE60324964D1 (de) 2002-07-15 2009-01-08 Univ Princeton Iap-bindende verbindungen
US7149755B2 (en) 2002-07-29 2006-12-12 Hewlett-Packard Development Company, Lp. Presenting a collection of media objects
US20080199439A1 (en) 2003-02-12 2008-08-21 Mclendon George L IAP-binding cargo molecules and peptidomimetics for use in diagnostic and therapeutic methods
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
CN1933847A (zh) 2004-01-16 2007-03-21 密歇根大学董事会 Smac肽模拟物及其应用
WO2005069894A2 (fr) 2004-01-16 2005-08-04 The Regents Of The University Of Michigan Mimetiques de smac contraints de maniere conformationnelle et utilisations associees
KR20060126548A (ko) 2004-02-05 2006-12-07 노파르티스 아게 (ａ) ＤＮＡ 토포이소머라제 억제제 및 (ｂ) ＩＡＰ 억제제조합물
AU2005228950B2 (en) 2004-03-23 2012-02-02 Genentech, Inc. Azabicyclo-octane inhibitors of IAP
CA2560162C (fr) 2004-04-07 2013-05-21 Novartis Ag Inhibiteurs d'iap
US7244851B2 (en) 2004-07-02 2007-07-17 Genentech, Inc. Inhibitors of IAP
WO2006010118A2 (fr) 2004-07-09 2006-01-26 The Regents Of The University Of Michigan Mimetiques de smac contraints par conformation et utilisations de ceux-ci
CA2573644A1 (fr) 2004-07-12 2006-02-16 Idun Pharmaceuticals, Inc. Analogues de tetrapeptide
WO2006020060A2 (fr) 2004-07-15 2006-02-23 Tetralogic Pharmaceuticals Corporation Composes de liaison aux proteines iap
JP2008016458A (ja) 2004-08-18 2008-01-24 Teijin Ltd 電磁波吸収シート材料
ATE477254T1 (de) 2004-12-20 2010-08-15 Genentech Inc Pyrrolidine als inhibitoren von iap
US20060228352A1 (en) * 2005-02-24 2006-10-12 Schoenberger Stephen P TRAIL and methods of modulating T cell activity and adaptive immune responses using TRAIL
CN101128425B (zh) * 2005-02-25 2012-12-26 泰特拉洛吉克药业公司 Iap二聚体抑制剂
US20070003535A1 (en) 2005-03-17 2007-01-04 Reed John C Methods and compositions for derepression of IAP-inhibited caspase
US7763604B2 (en) 2005-05-16 2010-07-27 Thallion Pharma Ceuticals, Inc. Methods for administration of a farnesyl dibenzodiazepinone
EP1883627B1 (fr) 2005-05-18 2018-04-18 Pharmascience Inc. Composes liants de domaine bir
EP1888619B1 (fr) 2005-05-25 2013-04-17 2cureX ApS Composés pour la modification de l'apoptose
BRPI0611922A2 (pt) 2005-06-08 2010-10-05 Novartis Ag compostos orgánicos
CA2617642A1 (fr) 2005-08-09 2007-02-22 Tetralogic Pharmaceuticals Corporation Traitement des maladies proliferatives
US20070203749A1 (en) 2005-08-09 2007-08-30 Sri Chunduru Business methods for compounds for treatment of proliferative disorders
WO2007048224A1 (fr) 2005-10-25 2007-05-03 Aegera Therapeutics Inc. Composés de liaison au domaine iap bir
EP1973899A4 (fr) 2005-12-19 2010-10-20 Genentech Inc Inhibiteurs iap
CA2632256A1 (fr) 2005-12-20 2007-07-05 Novartis Ag Combinaison de composes organiques
WO2007101347A1 (fr) 2006-03-07 2007-09-13 Aegera Therapeutics Inc. Composés de liaison au domaine bir
TWI504597B (zh) 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
JP2009530424A (ja) 2006-03-21 2009-08-27 ジョイアント ファーマスーティカルズ、インク． 小分子アポトーシスプロモーター
JP5230610B2 (ja) 2006-05-05 2013-07-10 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 二価ｓｍａｃ模倣物およびその使用
US8202902B2 (en) 2006-05-05 2012-06-19 The Regents Of The University Of Michigan Bivalent SMAC mimetics and the uses thereof
MY159563A (en) 2006-05-16 2017-01-13 Pharmascience Inc Iap bir domain binding compounds
US20100113326A1 (en) 2006-07-24 2010-05-06 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US20100056495A1 (en) 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
JP5452223B2 (ja) 2006-07-24 2014-03-26 テトラロジック ファーマシューティカルズ コーポレーション Ｉａｐ阻害剤
CL2007002167A1 (es) * 2006-07-24 2009-01-23 Tetralogic Pharm Corp Compuestos derivados de indol, antagonistas iap; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de cancer.
US20100144650A1 (en) 2006-07-24 2010-06-10 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US20100143499A1 (en) 2006-07-24 2010-06-10 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
PE20080951A1 (es) 2006-08-02 2008-09-11 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
JP2010507096A (ja) 2006-10-19 2010-03-04 ノバルティス アーゲー 有機化合物
KR20090094461A (ko) 2006-12-19 2009-09-07 제넨테크, 인크. Ｉａｐ의 이미다조피리딘 억제제
AU2008240153B2 (en) 2007-04-12 2013-01-31 Joyant Pharmaceuticals, Inc. SMAC mimetic dimers and trimers useful as anti-cancer agents
WO2008134679A1 (fr) 2007-04-30 2008-11-06 Genentech, Inc. Inhibiteurs de iap
US20110008802A1 (en) 2007-05-07 2011-01-13 Tetralogic Pharmaceuticals Corp. TNFalpha GENE EXPRESSION AS A BIOMARKER OF SENSITIVITY TO ANTAGONISTS OF INHIBITOR OF APOPTOSIS PROTEINS
AU2009206588A1 (en) 2008-01-24 2009-07-30 Tetralogic Pharmaceuticals Corporation IAP inhibitors
CA2736505A1 (fr) 2008-09-17 2010-03-25 Tetralogic Pharmaceuticals Corp. Inhibiteurs d'iap
US20120015352A1 (en) 2009-01-29 2012-01-19 Otto-Von-Guericke-Universitat Magdeburg Method of determining sensitivity of human or non-human animal cells to an iap antagonist
AU2010254209A1 (en) 2009-05-28 2011-12-15 Tetralogic Pharmaceuticals Corp. IAP inhibitors
EP2434890A4 (fr) 2009-05-28 2013-01-02 Tetralogic Pharm Corp Inhibiteurs de protéines d'apoptose
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
AU2012315986A1 (en) 2011-09-30 2014-04-17 Srinivas Chunduru Smac mimetic (birinapant) for use in the treatment of proliferative diseases (cancer)
US20130196927A1 (en) 2012-01-27 2013-08-01 Christopher BENETATOS Smac Mimetic Therapy
JP2015524441A (ja) 2012-08-01 2015-08-24 テトラロジック ファーマシューティカルズ コーポレーション 併用療法
WO2014121178A1 (fr) 2013-02-04 2014-08-07 Tetralogic Pharmaceuticals Corp. Procédé de traitement par mimétique de smac
US20140303090A1 (en) 2013-04-08 2014-10-09 Tetralogic Pharmaceuticals Corporation Smac Mimetic Therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080119532A1 (en) * 2004-03-01 2008-05-22 Board Of Regents, The University Of Texas System Dimeric Small Molecule Potentiators of Apoptosis
US20060194741A1 (en) * 2005-02-25 2006-08-31 Condon Stephen M Dimeric IAP inhibitors

Also Published As

Publication number Publication date
IL217237A0 (en) 2012-02-29
EA201171494A1 (ru) 2012-06-29
EP2448923A1 (fr) 2012-05-09
US20170182116A1 (en) 2017-06-29
US10596220B2 (en) 2020-03-24
WO2011002684A1 (fr) 2011-01-06
US20130012564A1 (en) 2013-01-10
AU2010266525C1 (en) 2015-10-01
BRPI1013958A2 (pt) 2019-09-03
US20190255139A1 (en) 2019-08-22
CA2766162A1 (fr) 2011-01-06
US20200282002A1 (en) 2020-09-10
DK2448923T3 (en) 2016-02-29
ES2565337T3 (es) 2016-04-04
US10314881B2 (en) 2019-06-11
JP2012532129A (ja) 2012-12-13
BRPI1013958B1 (pt) 2022-04-05
US20150158908A1 (en) 2015-06-11
JP5674780B2 (ja) 2015-02-25
US20110003877A1 (en) 2011-01-06
US11351221B2 (en) 2022-06-07
US20180303897A1 (en) 2018-10-25
EP2448923B8 (fr) 2016-01-27
HUE026982T2 (en) 2016-08-29
US8986993B2 (en) 2015-03-24
SG177404A1 (en) 2012-02-28
US11951147B2 (en) 2024-04-09
KR101755218B1 (ko) 2017-07-07
US8283372B2 (en) 2012-10-09
US20140073579A1 (en) 2014-03-13
ZA201109342B (en) 2014-05-28
AP2012006066A0 (en) 2012-02-29
CO6480975A2 (es) 2012-07-16
US8603816B2 (en) 2013-12-10
EP2448923B1 (fr) 2015-11-25
CN102471275B (zh) 2014-05-28
PE20131173A1 (es) 2013-10-03
AU2010266525A1 (en) 2012-01-19
MY153116A (en) 2014-12-31
NZ597051A (en) 2013-10-25
EA022061B1 (ru) 2015-10-30
HK1171022A1 (en) 2013-03-15
TW201113276A (en) 2011-04-16
IL217237A (en) 2014-09-30
EP2448923A4 (fr) 2013-05-01
ECSP11011557A (es) 2012-06-29
CL2011003333A1 (es) 2012-07-20
TWI485148B (zh) 2015-05-21
CN102471275A (zh) 2012-05-23
HK1169410A1 (zh) 2013-01-25
MX2011013819A (es) 2012-06-08
US20230149500A1 (en) 2023-05-18
CA2766162C (fr) 2018-07-24
US20120115922A1 (en) 2012-05-10
AU2010266525B2 (en) 2015-05-21
KR20120047905A (ko) 2012-05-14
US10034912B2 (en) 2018-07-31
AR077629A1 (es) 2011-09-14

Similar Documents

Publication Publication Date Title
AP3619A (en) Smac mimetic
HK1168791A1 (en) Substituted imidazoquinoxalines
ZA201202612B (en) Combination
GB0913314D0 (en) Facilitated percist evaluation
HK1174617A1 (en) Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts -1----2---
EP2456311A4 (fr) Imidasotriazines substituées
IL219103A0 (en) Combination
ZA201108565B (en) Substituted piperidnes
EP2448583A4 (fr) 4-hydroxypyrimidine-5-carboxamides substitués
HRP20130675T1 (en) Carpet
IL219786A0 (en) Combination
ZA201202494B (en) Combination
ZA201202173B (en) Combination
ZA201202495B (en) Combination
ZA201202258B (en) Combination
GB201018261D0 (en) Horizontallaufer-turbine mit passiver gierwinkel-einstellvorrichtung
IL218801A0 (en) Combination
EP2448584A4 (fr) 4-hydroxypyrimidine-5-carboxamides substitués
GB0918072D0 (en) Reverse-safe mode
GB0901391D0 (en) Combination
GB0906696D0 (en) Combination
GB0900563D0 (en) New combination
GB0900167D0 (en) B b